Sapient Capital LLC Has $741,000 Stock Holdings in Stryker Corporation $SYK

Sapient Capital LLC trimmed its stake in Stryker Corporation (NYSE:SYK) by 54.1% in the first quarter, Holdings Channel reports. The firm owned 2,250 shares of the medical technology company’s stock after selling 2,647 shares during the quarter. Sapient Capital LLC’s holdings in Stryker were worth $741,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Varma Mutual Pension Insurance Co lifted its stake in Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after purchasing an additional 5,100 shares during the last quarter. QRG Capital Management Inc. increased its position in Stryker by 7.4% during the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after buying an additional 4,186 shares during the last quarter. Fulton Breakefield Broenniman LLC raised its stake in Stryker by 41.3% in the fourth quarter. Fulton Breakefield Broenniman LLC now owns 50,123 shares of the medical technology company’s stock valued at $17,617,000 after buying an additional 14,641 shares during the period. Swedbank AB raised its stake in Stryker by 6.6% in the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after buying an additional 7,934 shares during the period. Finally, Crossmark Global Holdings Inc. lifted its position in shares of Stryker by 31.1% in the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after buying an additional 6,367 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Trading Up 4.6%

SYK stock opened at $340.73 on Tuesday. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a market capitalization of $130.62 billion, a PE ratio of 35.31, a price-to-earnings-growth ratio of 2.08 and a beta of 0.76. The company’s 50-day simple moving average is $317.77 and its 200 day simple moving average is $334.62. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 15.01 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Tuesday, June 30th were issued a $0.88 dividend. The ex-dividend date was Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio is presently 36.48%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on SYK shares. Raymond James Financial set a $370.00 target price on Stryker in a report on Friday. Canaccord Genuity Group reduced their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Wells Fargo & Company dropped their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Finally, UBS Group started coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.